Clinical Trials

Inclusion Criteria:

• Surgeon's estimated survival ≥ 1 month 
• Presenting for orthopaedic evaluation with a painful impending pathologic femur fracture or displaced pathologic femur fracture in the intertrochanteric, pertrochanteric, or subtrochanteric region of the proximal femur
  • The anatomic region of interest is defined by a line drawn from the base of the femoral neck to 5 cm below the base of the lesser trochanter or 2 diaphyseal shaft widths, whichever is greater
• An impending fracture and has had bevacizumab if there will be a 3-week window between the last infusion and surgery
• Diagnosis of widespread visceral and/or osseous metastatic disease based on clinical and radiographic evidence (may continue on study if surgery shows a non-malignant process)
• All cancer diagnoses, except lymphoma

Exclusion Criteria:

• Estimated survival <1 month
• A large soft tissue mass or other disease involving an area outside of the defined pertrochanteric anatomic region described above (if based on intraoperative findings, will be replaced on the study)
• Prior surgical treatment of the area (i.e., revision cases)
  • A biopsy does not constitute prior surgical treatment
• Radiographic evidence of an intramedullary occlusion by blastic metastases that would necessitate an alternative method of treatment, such as a plate/screw construct
• Diagnosis of lymphoma
• Age < 18 years
• Advanced hip arthritis on radiographic imaging
• Previous randomization for a contralateral procedure as part of this study